Leucid Bio

CAR-T therapy rewrote the rules for blood cancers. Engineer a patient's own T cells to recognize a tumor, infuse them back, and watch leukemias and lymphomas melt away. Then the field hit a wall: solid tumors - the lung, ovarian, and pancreatic cancers that make up the bulk of the disease - barely responded. Leucid Bio, a clinical-stage biotech founded in 2014 out of King's College London, was built around a specific answer to why.

The company's thesis starts with the receptor itself. Conventional CARs stack their signalling machinery in a linear, vertical column that projects out from the cell. Leucid's founder, Dr John Maher, spent more than 20 years arguing that nature does it differently: real immune receptors distribute their signalling domains laterally, alongside the cell membrane. Leucid Bio's proprietary Lateral CAR platform recapitulates that architecture. The internal shorthand is blunt - "build out, not down."

The claim is that a receptor closer to natural biology signals more faithfully: enhanced potency where you want it, reduced toxicity where you don't. It is an engineering argument, not a marketing one, and Leucid is now testing it in patients.

The model. Leucid Bio is a venture-funded, clinical-stage company - not yet a commercial one. It creates value by advancing its Lateral CAR pipeline through the clinic on specialist life-science capital, with eventual routes including partnership, licensing, or acquisition by a larger pharmaceutical company. Reported revenue reflects grants and early activity rather than product sales.

The customers. The ultimate beneficiaries are patients with refractory solid tumors - including platinum-resistant ovarian and other advanced cancers - treated through clinical trials at UK hospital sites. Near-term stakeholders are the investors, academic collaborators, and clinical investigators moving LEU011 forward.

The competition. Leucid works in a crowded field of solid tumor cell therapy - Celyad Oncology, Autolus, Adaptimmune, T-knife, and various academic NKG2D programs among them. Its differentiator is architectural: rather than a new target alone, it changes the shape of the receptor itself, betting that design - not dose - is what solid tumors have been waiting on.

The people

CEO Filippo Petti joined in July 2023 after serving as CEO, CFO, and Executive Director of Celyad Oncology. He sits opposite scientific founder Dr John Maher, whose two decades of King's College London research the company exists to translate - the recurring pattern in good biotech: a founder who won't quit paired with an operator who has shipped before.